Member Info for B2HS2L

yes a_g,
The only IT-IS vacancies I have seen have specifically stated the location as Stokesley or Middlesbrough.
A brief check has not revealed any current vacancies at Stokesley.

I am conscious that any R&D in development at the time of acquisition would have become the property of NCYT, but it may not have amounted to much, or it could be quite substantial.
The last new project was delivered I believe in 2019 with the Q32 / MyGoPro instrument.
Only time will tell.

ak_gabba, -
I always thought that bonus was not completely right, because GM had Chartwell pencilled in, to give the production capacity the kick up the backside it needed.

So that leaves the IT-IS directors perfecting some R&D they had started, - which poses the question 'on what'?
or
They are the specialists on whom Chartwell rely to get product development answers.
For instance when the Q16 / Q32 needed to be modified into an iso-thermal instrument for use with the proposed LAMP assay.

I hope GM is getting a lot of bang for his buck in this regard.

Would we not be looking at IT-IS recruitment to identify this kind of recruitment?

ChasPB -
Airline staff have been refusing to fly to China for this reason.

Hmmm, - wonder how airlines manage to find the staff to operate there.

Kaeren -
" She was asked specifically about Boris's statement regarding LFT's and flying. Her response was Boris has a balancing act to please the people , the head of Ryan and be mindful of what his chief scientists say. She said Boris is privy to and reminded daily how dangerous variants could be and has until the 17th of May to decide what to do. It could be that he has diff rules if arriving from a green zone , as opposed to a red zone."

On the face of it, Boris might be testing the water, seeing the reaction some of his 'options' get from the press and public.

One other thing might be at play here, - Boris might be aware of an LFT test he expects to be able to use, that allows the test result to be taken to the bank.
ie A VERY high Specificity and Sensitivity", with a sample taken from any of the usual places.

Just a thought.

ShaunP -

re your "PLUS The CEO of CCL is Tony Cooke. He is also Director of ReCoVa-19."
Tony Cooke was a big piece of Lab21's past.

From:
https://www.camclinlabs.co.uk/about-us

Cambridge Clinical Laboratories started its journey as Lab 21 in 2005.

The objective for the company was to be a lab for the 21st century – a lab that would be an early adopter of new technologies for diagnostics.

CCL CEO Tony Cooke, was a founding member of Lab21:
Product Development Director/Operations Director
Lab21 Ltd.
Dates Employed Apr 2005 – Jul 2013

27.11.2019 - Lab 21 becomes Cambridge Clinical Laboratories and pledges to offer revolutionary diagnostic tests

https://www.cambridgeindependent.co.uk/business/lab-21-becomes-cambridge-clinical-laboratories-and-pledges-to-offer-revolutionary-diagnostic-tests-9091608/

And one for our French Brethren to appreciate. - Et un pour nos Français frères d’apprécier.
No chocolate and it's not Easter, but the punchline is good..

https://www.bing.com/videos/search?q=my+mother+said+I+could&&view=detail&mid=6EAEE511F4662BC3CD9C6EAEE511F4662BC3CD9C&&FORM=VRDGAR

Appologies, - missed off the link:

https://www.mesabiotech.com/press-release/mesa-biotech-to-receive-funding-from-us-health-and-human-services-for-development-of-a-30-minute-molecular-pcr-point-of-care-sars-cov-2-test/

Indeed MS, their still FDA EUA, but with caveats, that the FDA are clarifying.
Rather unfortunate that T-F bought Mesa, but subsequently found there was a problem not only with their own test but Mesa's too.
Still, they should get their money back and more with Mesa's NPT Winterplex.
Don't believe NCYT ever applied for EUA, - but I might soon be proved wrong.

The following article seems to imply that Mesa's technology was developed with plenty of Govnt money.
T-F paid $450 Mil for Mesa in January, and most of it's assets were courtesy of the US taxpayer by the look of it.

A FAST & SENSITIVE ANTIGEN TEST FOR COVID-19

https://perkinelmer-appliedgenomics.com/home/sars-cov-2-testing-solutions/perkinelmer-covid-19-antigen-test/#utm_source=Genome%20Web&utm_medium=Newsletter&utm_campaign=AGN-COR-2021-GLO-SE-Newsletter-ZZ-GWAntigen

For competition awareness only.

Finally – A Simple, Rapid, and Reliable Test for COVID-19
The PerkinElmer COVID-19 Antigen Test is a CE marked in vitro diagnostic device for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigen in nasal or nasopharyngeal swab specimens. The lateral flow immunoassay test can be used to screen or aid in the diagnosis of COVID-19 in asymptomatic or symptomatic individuals. A positive or negative result can be obtained as early as 15 minutes to facilitate immediate isolation or treatment decisions.

The test is ideally suited for point-of-care (POC) clinical and non-clinical settings such as healthcare centers, travel hubs, businesses and educational institutions. Clinical studies in symptomatic and asymptomatic populations, including individuals with low viral load, have shown sensitivity >97% amongst all samples. Specificity of the test across 202 negative samples was 100%, which means no false positives were identified. The PerkinElmer COVID-19 Antigen Test was tested against the most-sensitive commercially available RT-PCR kit on the market (FDA Reference Panel Comparative Data. Oct. 2, 2020)+.

HarChris, -

It's my hunch that the acquisition(s) are going to form the Non-Covid future for NCYT, - but just a guess.
Perhaps in Transplants?

Sorry to hear you won't continue with your previous position Airlineboy, but wish you success with your efforts to find another position or career. My colleague has lost his job at an aircraft simulator manufacturer, but I think he is well prepared and may not need another position. Last month Airbus manufactured their last A380, - grim.

In fact, - a lot more than just vaccine.
Hope this cheers you up Airlineboy:

https://www.iata.org/en/pressroom/pr/2021-03-17-04/

17.03.2021

IATA Travel Pass Successfully Trialled on First International Flight

Geneva – The International Air Transport Association (IATA) announced the arrival at London’s Heathrow Airport of the first traveller using the IATA Travel Pass app to manage their travel health credentials.

“The successful implementation of IATA Travel Pass in this trial with Singapore Airlines passengers demonstrates that technology can securely, conveniently and efficiently help travellers and governments to manage travel health credentials. The significance of this to re-starting international aviation cannot be overstated,” said Alexandre de Juniac, IATA’s Director General and CEO.

https://youtu.be/R4f1r5iogAo

At 0.30 It talks about use of verified vaccination details.

Still need to get individual governments to agree to this, but IATA is trying to bust us out of jail,
and no-one better placed than IATA to succeed.

Squadra
'For how long Nova will remain independent ?'

bottom of page 56 in 00) spreadsheet (Protection from foreign takeovers) are three pieces of legislation that any company interested in acquiring NCYT would have to successfully navigate, - and IMO this is part of the reason why T/O activity has not included Novacyt this year, - at least not yet.
If this is correct, then GM's chances of making Novacyt a 'big hitter' have improved somewhat.

Squadra -

Should there be any M&A / Merger negotiations GM would want a good lawyer, - so I wonder how good is his M&A experience?

Graham has a lot of M&A negotiating experience, and will have seen the strong and weak side of previous legal council.

M&A might mean Nick needs to become familiar with foreign law, should the other party be non-UK.

I am confident Graham knows what he is looking for, and has found his man.

GM put Anthony Dyer into the Chief Corporate Development Officer role anticipating a H1 acquisition,

so I suppose legal council to facilitate a deal, or assist with defending a hostile Takeover attempt, is now due.

I also think an RNS is in order on this new addition (CE-IVD ) to the catalogue, particularly as it is common knowledge tenders looking for such tests are currently out there.

When the new Novacyt Group Twitter platform was opened, I did not take it that GM was responding to calls for more openness and greater Shareholder engagement.
I felt it might be used to announce some of the new products which would normally be the subject of an RNS.
Unfortunately events are proving that RNS - able subjects, Shareholder engagement AND market communications material are being published via twitter.

Anyone know of another company preferring not to RNS but publish via social media?

From 16.11.2020 RNS
"Development of an antibody lateral flow test for COVID-19
On 29 September 2020, Novacyt announced the launch of its IgG specific antibody test for use in central laboratory testing.
The Company is also working on developing an IgG antibody lateral flow test (LFT) for use as a rapid antibody test for professional use.
An LFT is an easy-to-use diagnostic device used to confirm the presence or absence of a pathogen or biomarker.
The product is expected to launch during Q1 2021 and is expected to take approximately 20 minutes or less to give a result."
++++

https://microgenbioproducts.com/pathflow-2/

The PathFlow® SARS-CoV-2 IgG is an easy-to-use, rapid, lateral flow test, for the detection of antibodies in human whole blood, serum, or plasma specimen(s).

Rapid results – 10-20 minutes
Sample types – Whole Blood/Serum/Plasma
Sensitivity – 98%
Specificity – 99%
Product code M598CE | 25 tests

Sorry to hear of bad news Wilson, I hope this helps:
++++
John had been having constant headaches ever since his teenage years.

His doctor had tried many cures, but the headaches persisted.

One day, the doctor asks John to take off his trousers.

After examining John, he thinks he sees the problem.

"You have a rare condition," explains the doc.

"Your testicl*s are pressed up against your spinal cord, giving you headaches.

This condition has only one cure: Castrati*n."

So John agrees to Castrati*n, and after successful surgery, is so relieved his headaches are gone, he decides to go clothes shopping.

He enters a very high class tailor's shop and says to the tailor, "I'd like to buy a new shirt, please." But before he can tell the tailor his shirt size, the tailor has already produced a shirt.

John inspects the shirt closely. Much to his amazement, the tailor has gotten all the measurements exactly right.

Then he asks for a new pair of trousers. The tailor gives him a pair of trousers, and once again, he gets all the measurements exactly right.

"This is all well and good," says John, "but you might need some help selecting the right underwear."

When the tailor gives him the underwear, John says "That's the first thing you've got wrong - I take a Medium, not a Large"

"Are you sure?" asks the tailor. "Because a size M would press your testicles against your spinal cord, and you'd get a terrible headache."

Hi Exmex.

Missing section V thought to be 'Award of Contract'. - Hence reason for it's absence :0)

Hi Exmex, - Thanks for the heads up.
No section V. - Would we normally expect one, and if so what might be the subject matter?

Just trying to establish if we have 100% of the information.